Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes: Role of CYP3A4

Drug Metabolism and Disposition

Volumn 24, Issue 9, 1996, Pages 932-939

  Feierman, Dennis E ^a,b   Lasker, Jerome M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ENZYME INHIBITOR; FENTANYL; FENTANYL DERIVATIVE; OPIATE; POLYCLONAL ANTIBODY;

ARTICLE; DRUG METABOLISM; DRUG OXIDATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; KINETICS; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

ANALGESICS, OPIOID; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; FENTANYL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; KETOCONAZOLE; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; THEOPHYLLINE; TOLBUTAMIDE;

EID: 0029813838     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. K. A. Lehmann, G. Moseler, and D. Daub: Biotransformation von Fentanyl. I. In vitro abbau durch gewebe der Maus. Anaesthesist 30, 461-466 (1981).
2. K. A. Lehmann, C. Weski, L. Hunger, C. Heinrich, and D. Daub: Biotransformation von Fentanyl. II. Akute Arzneimittelinteraktioen-Untersuchungen bei Ratte und Mensch. Anaesthesist 31, 221-227 (1982).
3. K. A. Lehmann, L. Hunger, K. Brandt, and D. Daub: Biotransformation von Fentanyl. III. Einflusse chronischer arzneimittelexposition auf verteilung, metabolismus und Ausscheidung bei der Ratte. Anaesthesist 32, 165-173 (1983).
4. J. P. Haberer, P. Schoeffler, E. Couderc, and P. Duvaldesrin: Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br. J. Anaesth. 54, 1267-1270 (1982).
5. I. Van Wijngaarden and W. Soudijn: The metabolism and excretion of the analgesic fentanyl (R-4263) by Wistar rats. Life Sci. 7, 1239-1244 (1968).
6. H. H. Van Rooy and N. P. E. Vermeulen: The assay of fentanyl and its metabolites in the plasma of patients using gas chromatography with alkali flame ionization detection and gas chromatography-mass spectrometry. J. Chromatogr. 223, 85-93 (1981).
7. T. Goromaru, H. Matsuura, N. Yoshimura, T. Miyawaki, T. Semeshima, J. Miyao, T. Furuta, and S. Baba: Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography-mass spectrometry. Anesthesiology 61, 73-77 (1984).
8. Y. Maruyama and E. Hosoya: Studies on the fate of fentanyl. Keio J. Med. 18, 59-70 (1969).
9. W. Meuldermans, J. Hendrickx, W. Lauwers, R. Hurkmans, E. Swysen, J. Thijssen, P. Timmerman, R. Woestenborghs, and J. Heykants: Excretion and biotransformation of alfentanil and sufentanil in rats and dogs. Drug Metab. Dispos. 15, 905-913 (1987).
10. K. Lavrijsen, J. Van Houdt, D. Van Dyck, J. Hendrickx, W. Lauwers, R. Hurkmans, M. Bockx, C. Janssen, W. Meuldermans, and J. Heykants: Biotransformation of sufentanil in liver microsomes of rats, dogs and humans. Drug Metab. Dispos. 18, 704-710 (1990).
11. C. Yun, M. Wood, A. J. J. Wood, and F. P. Guengerich: Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P450 3A4. Anesthesiology 77, 467-474 (1992).
12. E. D. Kharasch and K. E. Thummel: Human alfentanil metabolism by cytochrome P450 3A3/4, an explanation for the interindividual variability in alfentanil clearance. Anesth. Anal. 76, 1033-1039 (1993).
13. R. B. Labroo, K. E. Thummel, K. L. Kunze, T. Podoll, W. F. Trager, and E. D. Kharasch: Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab. Dispos. 23, 490-496 (1995).
14. J. L. Raucy and J. M. Lasker: Purification of P450 enzymes from human liver. Methods Enzymol. 208, 577-587 (1991).
15. P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gärtner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk: Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85 (1985).
16. T. Omura and R. Sato: Carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378 (1964).
17. J. M. Lasker, J. L. Raucy, S. Kubota, B. P. Bloswick, M. Black, and C. S. Lieber: Purification and characterization of human liver P450-ALC. Biochem. Biophys. Res. Commun. 148, 232-238 (1987).
18. F. J. Gonzalez, B. J. Schmid, M. Umeno, O. W. McBride, J. P. Hardwick, U. A. Meyer, H. V. Gelboin, and J. R. Idle: Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7, 79-86 (1988).
19. M. Tsutsumi, J. M. Lasker, M. Shimizu, A. S. Rosman, and C. S. Lieber: The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology 10, 437-446 (1989).
20. M. M. McKinney and A. Parkinson: A simple, non-chromatographic procedure to purify immuno-globulin from serum and ascites fluid. J. Immunol. Methods 96, 271-278 (1987).
21. J. L. Raucy, J. M. Lasker, C. S. Lieber, and M. Black: Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch. Biochem. Biophys. 271, 270-283 (1989).
22. J. H. Silverstein, M. F. Rieders, M. McMullin, S. Schulman, and K. Zal: An analysis of the duration of fentanyl and its metabolites in urine and saliva. Anesth. Analg. 76, 618-621 (1993).
23. J. A. Goldstein, M. B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. L. Raucy, J. Blaisdell, J. M. Lasker, and B. I. Ghanayem: Evidence for a role for P4502C19 in the metabolism of S-mephenytoin in humans. Biochemistry 33, 1743-1752 (1994).
24. D. J. Newton, R. W. Wang, and A. Y. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
25. P. B. Watkins, S. A. Wrighton, P. Maurel, E. G. Schuetz, G. Mendez-Picon, and G. A. Parker: Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA 82, 6310-6314 (1985).
26. F. P. Guengerich, M. V. Martin, P. H. Beaune, P. Kremers, T. Wolff, and D. J. Waxman: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051-5060 (1986).
27. T. Kornbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36, 89-96 (1989).
28. T. Kronbach, V. Fischer, and U. A. Meyer: Cyclosporine metabolism in human liver: identification of a cytochrome P450-III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43, 630-635 (1988).
29. R. W. Wang, P. H. Kari, A. Y. H. Lu, P. E. Thomas, F. P. Guengerich, and K. P. Vyas: Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290, 355-361 (1991).
30. M. J. Bargetzi, T. Aoyama, F. J. Gonzalez, and U. A. Meyer: Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin. Pharmacol. Ther. 46, 521-527 (1989).
31. S. Imaoka, K. Enomoto, Y. Oda, A. Asada, M. Fujimori, T. Shimada, S. Fujita, F. P. Guengerich, and Y. Funae: Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther. 255, 1385-1390 (1990).
32. K. T. Olkkola, K. Aranko, H. Luurila, A. Hiller, L. Saarnivaara, J. J. Himberg, and P. J. Neuvonen: A potentially hazardous interaction between erythromycin and midazolam. Clin. Pharmacol. Ther. 53, 298-305 (1993).
33. K. T. Olkkola, J. T. Backman, and P. J. Neuvonen: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55, 481-485 (1994).
34. D. H. Spach, J. E. Bauwens, C. D. Clark, and W. G. Burke: Rhabdomyolosis associated with lovastatin and erythromycin use. West. J. Med. 154, 213-215 (1991).
35. J. C. Gorski, S. D. Hall, D. R. Jones, M. VandenBranden, and S. A. Wrighton: Regioselective biotransformation of midazolam by members of the cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47, 1643-1653 (1994).
36. R. R. Bartowski, M. E. Goldberg, G. E. Larijani, and T. Boerner: Inhibition of alfentanil metabolism by erythromycin. Clin. Pharmacol. Ther. 46, 99-102 (1989).
37. D. R. Nelson, T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyeresein, Y. Fujii-Kuriyama, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda, and D. W. Nebert: The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names, and nomenclature. DNA Cell. Biol. 12, 1-51 (1993).
38. J. D. Schuetz, D. L. Beach, and P. S. Guzelian: Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4, 11-20 (1994).
39. W. Meuldermans, J. Van Peer, J. Hendrickx, R. Woestenborghs, W. Lauwers, J. Heykants, G. Vanden Bussche, H. Van Craeyvelt, and P. Van Der Aa: Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 69, 527-534 (1988).
40. T. Tateishi, Y. Krivoruk, Y.-F. Ueng, A. J. J. Wood, F. P. Guengerich, and M. Wood: Identification of human liver cytochrome P450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth. Analg. 82, 167-172 (1996).